Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model

16 Dec 2020

Abstract excerpt

Peroxisome proliferator-activated receptor α/δ (PPAR α/δ), regulating glucolipid metabolism and immune inflammation, has been identified as an effective therapeutic target in non-alcoholic steatohepatitis (NASH). Dual PPAR α/δ agonist, such as GFT505 (also known as elafibranor), demonstrated potential therapeutic effect for NASH in clinical trials. To profile the regulatory network of PPAR α/δ agonist in NASH,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diet, Metabolism, and Disease
Share to Liver Disease Diagnosis and Treatment
Share to Peroxisome Proliferator-Activated Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33326461
DOI: 10.1371/journal.pone.0243911

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH modelPMID 33326461Read ↗

Roles of PPARα and PPARγ As Regulator of Free Fatty Acids in Nonalcoholic SteatohepatitisSemantic proximity Read ↗

The Study of Yin-Chen-Hao-Tang Preventing and Treating Alcoholic Fatty Liver Disease Through PPAR Signaling Pathway Based on Network Pharmacology and RNA-Seq TranscriptomicsSemantic proximity Read ↗

PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progressionSemantic proximity Read ↗

Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver diseaseSemantic proximity Read ↗

Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontinSemantic proximity Read ↗

Hepatocyte PPARγ contributes to the progression of non-alcoholic steatohepatitis in male and female obese miceSemantic proximity Read ↗

Comparative Transcriptional Network Modeling of Three PPAR-α/γ Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human HepatocytesSemantic proximity Read ↗

Enpp1 ameliorates NAFLD by regulating hepatocyte lipid metabolism through the AMPK/PPARα signaling pathwaySemantic proximity Read ↗

Orchestration of Gut–Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic InnovationSemantic proximity Read ↗

Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug targetSemantic proximity Read ↗

The Effect of Cardiometabolic Drugs on Non-Alcoholic Fatty Liver Disease (NAFLD), Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Semantic proximity Read ↗

Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.